PT Darya-Varia Laboratoria (DVLA) Fundamentals 2026 — P/E 12.6x, Revenue Analysis | SniperIQ
PT Darya-Varia Laboratoria (DVLA) is a ID-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of Rp1.77T, trading at Rp1580.00 on the JKT. This SniperIQ fundamentals page covers PT Darya-Varia Laboratoria's valuation (P/E 12.6x, P/B 1.2x), profitability (net margin 6.2%), revenue (Rp2.23T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Darya-Varia Laboratoria's market cap?
PT Darya-Varia Laboratoria (DVLA) has a market capitalization of approximately Rp1.77T, trading at Rp1580.00 on the JKT. Market cap moves with the live share price.
What is PT Darya-Varia Laboratoria's P/E ratio?
PT Darya-Varia Laboratoria's trailing twelve-month P/E ratio is 12.6x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Darya-Varia Laboratoria?
PT Darya-Varia Laboratoria runs a net profit margin of 6.2%, a gross margin of 51.5%, and an operating margin of 7.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Darya-Varia Laboratoria generate?
PT Darya-Varia Laboratoria reported revenue of Rp2.23T for fiscal year 2025, with net income of Rp163.9B and earnings per share (EPS) of 146.38. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Darya-Varia Laboratoria pay a dividend?
PT Darya-Varia Laboratoria offers a trailing dividend yield of about 6.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PT Darya-Varia Laboratoria financially healthy?
PT Darya-Varia Laboratoria carries a debt-to-equity ratio of 0.00x and a current ratio of 2.34x, with a market beta of -0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Darya-Varia Laboratoria a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Darya-Varia Laboratoria (DVLA) the key facts are: market cap Rp1.77T, P/E 12.6x, revenue Rp2.23T, 52-week range 1450-1715. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Darya-Varia Laboratoria's full fundamentals live
Get PT Darya-Varia Laboratoria's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.